DABRAFENIB 75MG

Product Description

DABRAFNIB is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.

Dabra is indicated, in combination with trametinib, for:

the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.

the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Limitations of Use: Dabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.

DOSAGE AND USE:

The recommended dosage of Dabra is 150 mg orally twice daily. Take Dabra at least 1 hour before or at least 2 hours after a meal.

Capsule should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20C to 25C.